Cancer Family
Secondary Neoplasm
CI-CAN-00000050Explore in graph →
Non-malignant4,276 active trials56 approved drugs532 evidence items
- NCIt
- C36255
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000050Explore in graph →
Clinical trials
14,673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05392413 | Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody | recruiting | — | 200 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05429216 | Endoscopic Resection for Small Rectal Neuroendocrine Tumors | not yet recruiting | N/A | 102 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Jul 1, 2022 | clinicaltrials |
| NCT04973306 | Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC(iCROSS) | recruiting | Phase 2 / Phase 3 | 176 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05188313 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer(TRAP-2) | recruiting | Phase 3 | 376 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05420480 | Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy | not yet recruiting | N/A | 323 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04499833 | HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma(HepatoPredict) | recruiting | N/A | 40 | Centro Hospitalar de Lisboa CentralOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT04807673 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)(KEYSTONE-002) | recruiting | Phase 3 | 342 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05388500 | Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)(PHARE-C) | not yet recruiting | Phase 3 | 800 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT04306458 | RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).(ROBOT-2) | recruiting | N/A | 218 | University Medical Center MainzOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT05037825 | The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors(PARADIGM) | recruiting | — | 800 | VastBiomeINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT02938702 | Active Surveillance on Papillary Thyroid Microcarcinoma | active not recruiting | — | 1,211 | Seoul National University HospitalOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT04666961 | Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ(HORNEO01) | recruiting | Phase 2 | 262 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT05323929 | The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma | recruiting | N/A | 200 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05323201 | Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer | recruiting | Phase 1 / Phase 2 | 15 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT04946773 | Deep Liver Phenotyping and Immunology Study(DELPHI) | recruiting | — | 100 | University of OxfordOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03836352 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | active not recruiting | Phase 2 | 184 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Mar 31, 2022 | clinicaltrials |
| NCT05291728 | Screening for Early Gastric Cancer in Shaanxi Province | recruiting | — | 12,500,000 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT05214885 | Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma | recruiting | — | 300 | Qianfoshan HospitalOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT05268692 | Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP | recruiting | Phase 2 / Phase 3 | 500 | Kochi UniversityOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT05044117 | Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) | recruiting | Phase 3 | 220 | Sun Yat-sen UniversityOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03308396 | Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | Ajjai Alva, MDOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT04712305 | Urine Omics Predicting IO Therapy Responses in mRCC Patients | recruiting | — | 400 | National Taiwan University HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT05155878 | Prognostic Factors in Periampullary Tumors and Cysts | recruiting | — | 500 | Umeå UniversityOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT04969731 | Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer | recruiting | Phase 3 | 408 | GC Cell CorporationINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT04009265 | Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma | recruiting | Phase 3 | 819 | Fujian Medical University Union HospitalOTHER | 1 | Nov 12, 2021 | clinicaltrials |
| NCT04595864 | Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation | recruiting | Phase 3 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT04018872 | Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer | recruiting | Phase 2 | 78 | Dallas VA Medical CenterFED | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04519905 | Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15) | recruiting | N/A | 320 | Fudan UniversityOTHER | 1 | Nov 2, 2021 | clinicaltrials |
| NCT05067530 | Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study(CAREGIVER) | not yet recruiting | Phase 2 | 126 | Medical University of GdanskOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT04455932 | HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation | recruiting | N/A | 476 | Concord Repatriation General HospitalOTHER | 2 | Sep 8, 2021 | clinicaltrials |
| NCT05022914 | PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE(PSICHE) | recruiting | — | 180 | Azienda Ospedaliero-Universitaria CareggiOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT04993014 | Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer(HER2Cell) | recruiting | Phase 2 | 80 | AC Camargo Cancer CenterOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT02073500 | Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies(PSM) | recruiting | — | 300 | Oslo University HospitalOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT04976478 | Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma | not yet recruiting | — | 125 | Peking University Third HospitalOTHER | 1 | Jul 26, 2021 | clinicaltrials |
| NCT04146077 | Active Surveillance for Low Risk Prostate Cancer | recruiting | — | 100 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT03787056 | Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients(ONCOPRO) | recruiting | N/A | 410 | Hospices Civils de LyonOTHER | 1 | Jul 16, 2021 | clinicaltrials |
| NCT03961776 | Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems(DWI_RECT_MRGRT) | recruiting | — | 39 | Institut Paoli-CalmettesOTHER | 2 | May 6, 2021 | clinicaltrials |
| NCT04829708 | Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy | recruiting | Phase 3 | 534 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT04777942 | Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA) | recruiting | N/A | 320 | Sun Yat-sen UniversityOTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT04595929 | Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-(GASPACCO) | recruiting | N/A | 304 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04634448 | The Prevalence of Appendiceal Tumours in Periappendicular Abscess(PeriAPPAC-T) | not yet recruiting | N/A | 400 | Turku University HospitalOTHER_GOV | 0 | Nov 18, 2020 | clinicaltrials |
| NCT03288532 | Renal Adjuvant MultiPle Arm Randomised Trial(RAMPART) | recruiting | Phase 3 | 1,750 | University College, LondonOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT04220749 | Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma | recruiting | Phase 2 | 68 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT04522687 | Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer | recruiting | — | 500 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT04481763 | A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast | recruiting | Phase 1 / Phase 2 | 20 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT04481932 | Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer | recruiting | Phase 2 | 104 | Peking UniversityOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT04150744 | RFA Plus Carrizumab vs Carrizumab Alone for HCC | recruiting | Phase 2 | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 8, 2020 | clinicaltrials |
| NCT04437160 | Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy | recruiting | Phase 2 | 286 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT04281641 | Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer(PHC-BC) | recruiting | N/A | 94 | Fudan UniversityOTHER | 1 | May 4, 2020 | clinicaltrials |
| NCT04365751 | To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma | recruiting | N/A | 1,134 | Chinese PLA General HospitalOTHER | 1 | Apr 28, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jul 6, 2022source: clinicaltrials